• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于肿瘤浸润淋巴细胞（TILs）分级的PD-1和PD-L1作为结直肠癌预后和预测生物标志物的潜力

The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading.

作者信息

Rasyid Nur Rahmah, Miskad Upik Anderiani, Cangara Muhammad Husni, Wahid Syarifuddin, Achmad Djumadi, Tawali Suryani, Mardiati Mardiati

机构信息

Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.

Anatomical Pathology Laboratory, Hasanuddin University Hospital, Makassar 90245, Indonesia.

出版信息

Curr Oncol. 2024 Nov 25;31(12):7476-7493. doi: 10.3390/curroncol31120552.

DOI:10.3390/curroncol31120552
PMID:39727675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11674277/
Abstract

AIM

Colorectal cancer (CRC) is a prevalent malignancy with a high mortality rate. Tumor-infiltrating lymphocytes (TILs) play a crucial role in the immune response against tumors. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are key immune checkpoints regulating T cells in the tumor microenvironment. This study aimed to assess the relationships among PD-1 expression on TILs, PD-L1 expression in tumors, and TIL grading in colorectal adenocarcinoma.

METHODS

A cross-sectional design was employed to analyze 130 colorectal adenocarcinoma samples. The expression of PD-1 and PD-L1 was assessed through immunohistochemistry. A semi-quantitative scoring system was applied. Statistical analysis with the chi-square test was performed to explore correlations, with the data analyzed in SPSS version 27.

RESULTS

PD-1 expression on TILs significantly correlated with a higher TIL grading ( < 0.001), while PD-L1 expression in tumors showed an inverse correlation with TIL grading ( < 0.001).

CONCLUSIONS

The expression of PD-1 on TILs and PD-L1 on tumor cells correlated significantly with the grading of TILs in colorectal adenocarcinoma. This finding shows potential as a predictive biomarker for PD-1/PD-L1 blockade therapy. Further studies are needed to strengthen these results.

摘要

目的

结直肠癌（CRC）是一种常见的恶性肿瘤，死亡率很高。肿瘤浸润淋巴细胞（TILs）在抗肿瘤免疫反应中起关键作用。程序性死亡蛋白1（PD-1）和程序性死亡配体1（PD-L1）是调节肿瘤微环境中T细胞的关键免疫检查点。本研究旨在评估结直肠腺癌中TILs上PD-1表达、肿瘤中PD-L1表达与TIL分级之间的关系。

方法

采用横断面设计分析130例结直肠腺癌样本。通过免疫组织化学评估PD-1和PD-L1的表达。应用半定量评分系统。采用卡方检验进行统计分析以探索相关性，数据在SPSS 27版中进行分析。

结果

TILs上的PD-1表达与较高的TIL分级显著相关（<0.001），而肿瘤中的PD-L1表达与TIL分级呈负相关（<0.001）。

结论

结直肠腺癌中TILs上的PD-1表达和肿瘤细胞上的PD-L1表达与TIL分级显著相关。这一发现显示出作为PD-1/PD-L1阻断治疗预测生物标志物的潜力。需要进一步研究来强化这些结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1cf/11674277/d3ae83228129/curroncol-31-00552-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1cf/11674277/17267a031ee8/curroncol-31-00552-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1cf/11674277/50e5c6b14623/curroncol-31-00552-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1cf/11674277/d3ae83228129/curroncol-31-00552-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1cf/11674277/17267a031ee8/curroncol-31-00552-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1cf/11674277/50e5c6b14623/curroncol-31-00552-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1cf/11674277/d3ae83228129/curroncol-31-00552-g003.jpg

相似文献

1
The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading.基于肿瘤浸润淋巴细胞（TILs）分级的PD-1和PD-L1作为结直肠癌预后和预测生物标志物的潜力
Curr Oncol. 2024 Nov 25;31(12):7476-7493. doi: 10.3390/curroncol31120552.
2
Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in colorectal adenocarcinoma.结直肠腺癌中的程序性死亡配体 1 表达和肿瘤浸润淋巴细胞。
Minerva Med. 2020 Aug;111(4):337-343. doi: 10.23736/S0026-4806.20.06401-0.
3
Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.结直肠癌中PD-L1表达及肿瘤浸润淋巴细胞的免疫分类
BMC Cancer. 2020 Jan 28;20(1):58. doi: 10.1186/s12885-020-6553-9.
4
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.程序性细胞死亡蛋白1（PD-1）和PD-配体1（PD-L1）在大肠癌细胞及肿瘤浸润淋巴细胞中的表达对结直肠癌的预后影响
Mol Cancer. 2016 Aug 24;15(1):55. doi: 10.1186/s12943-016-0539-x.
5
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.LAG-3 蛋白在非小细胞肺癌中的表达及其与 PD-1/PD-L1 和肿瘤浸润淋巴细胞的关系。
J Thorac Oncol. 2017 May;12(5):814-823. doi: 10.1016/j.jtho.2017.01.019. Epub 2017 Jan 26.
6
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).免疫检查点抑制剂的治疗候选物由三阴性乳腺癌（TNBC）中肿瘤浸润淋巴细胞（TILs）和程序性死亡配体 1（PD-L1）表达的状态所阐明。
Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.
7
PD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition.结直肠腺癌中 PD-L1 的表达与肿瘤免疫微环境和上皮-间充质转化相关。
Am J Clin Pathol. 2022 Oct 6;158(4):506-515. doi: 10.1093/ajcp/aqac077.
8
Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis.程序性死亡受体-1（PD-1）及其配体（PD-L1）在非小细胞肺癌中的表达与无氧糖酵解的免疫抑制作用。
Med Oncol. 2019 Jul 24;36(9):76. doi: 10.1007/s12032-019-1299-4.
9
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.胃肠胰神经内分泌肿瘤的免疫检查点标志物。
Endocr Relat Cancer. 2019 Mar 1;26(3):293-301. doi: 10.1530/ERC-18-0494.
10
Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.伊朗乳腺癌患者免疫检查点表达和淋巴细胞密度的特征；共表达状态与临床病理相关。
BMC Cancer. 2023 Jun 1;23(1):495. doi: 10.1186/s12885-023-11005-y.

本文引用的文献

1
Regulatory mechanisms of PD-1/PD-L1 in cancers.PD-1/PD-L1 在癌症中的调控机制。
Mol Cancer. 2024 May 18;23(1):108. doi: 10.1186/s12943-024-02023-w.
2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer.
CD3+/CD8+ 淋巴细胞浸润和 PD-L1 表达在结直肠癌中的预测价值。
Curr Oncol. 2023 Oct 31;30(11):9647-9659. doi: 10.3390/curroncol30110699.
4
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends.实体瘤的免疫检查点治疗：临床困境与未来趋势。
Signal Transduct Target Ther. 2023 Aug 28;8(1):320. doi: 10.1038/s41392-023-01522-4.
5
Colorectal cancer statistics, 2023.2023 年结直肠癌统计数据。
CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1.
6
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN.2020年和2040年全球结直肠癌负担：来自全球癌症负担（GLOBOCAN）的发病率和死亡率估计
Gut. 2023 Feb;72(2):338-344. doi: 10.1136/gutjnl-2022-327736. Epub 2022 Sep 8.
7
Tumour-infiltrating lymphocytes: from prognosis to treatment selection.肿瘤浸润淋巴细胞：从预后到治疗选择。
Br J Cancer. 2023 Feb;128(3):451-458. doi: 10.1038/s41416-022-02119-4. Epub 2022 Dec 23.
8
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems.病理学家的PD-L1图谱：适应证、评分、诊断平台及报告系统
J Pers Med. 2022 Jun 29;12(7):1073. doi: 10.3390/jpm12071073.
9
Immune Checkpoint Inhibitors in Cancer Therapy.癌症治疗中的免疫检查点抑制剂。
Curr Oncol. 2022 Apr 24;29(5):3044-3060. doi: 10.3390/curroncol29050247.
10
Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior.靶向肿瘤可塑性和癌症干细胞行为的表观遗传修饰物。
Cells. 2022 Apr 21;11(9):1403. doi: 10.3390/cells11091403.